Kyverna Therapeutics completes IPO of 16.7M shares at $22.00, gross proceeds $366.9M

Kyverna Therapeutics, Inc.

Gross proceeds $366.9M from IPO including full exercise of underwriter option to purchase 2.175M additional shares.
Shares listed on Nasdaq Global Select Market under ticker KYTX.
Amended charter and bylaws effective upon closing include classified board, exclusive forum provisions, and no cumulative voting.
Authorized capital: 490M shares of common stock and 10M shares of undesignated preferred stock.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Kyverna Therapeutics, Inc.: Amended and restated certificate of incorporation and bylaws effective upon closing of IPO, including provisions on capital stock, board classification, exclusive forum, and stockholder action by written consent prohibition (effective 2024-02-12).

Change: bylaw amendment
Effective: 2024-02-12

Exact text from the filing

On February 12, 2024, Kyverna Therapeutics, Inc. (the “Company”) filed an amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware, and the Certificate of Incorporation and its amended and restated bylaws (the “Bylaws”) became effective in connection with the closing of the initial public offering of shares of the Company’s common stock.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-032161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.